Fibroblast growth factor 23 and uremic vascular calcification: is it time to escalate from biomarker status to pathogenic agent?

Orson W Moe, Makoto Kuro-o
Kidney International 2014, 85 (5): 1022-3
Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"